Comparative Pharmacology
Head-to-head clinical analysis: EMRELIS versus MAXOLON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMRELIS versus MAXOLON.
EMRELIS vs MAXOLON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Emrelis is a monoclonal antibody that inhibits the interaction between programmed cell death protein 1 (PD-1) and its ligands PD-L1 and PD-L2, thereby activating T-cell-mediated antitumor immune response.
Metoclopramide, the active ingredient in MAXOLON, is a dopamine D2 receptor antagonist and also enhances the response to acetylcholine at muscarinic receptors in the gastrointestinal tract, leading to increased gastric motility and accelerated gastric emptying. It also has antiemetic effects by blocking dopamine receptors in the chemoreceptor trigger zone (CTZ).
100 mg subcutaneously once weekly.
10 mg orally, intramuscularly, or intravenously three to four times daily. Maximum daily dose: 30 mg or 0.5 mg/kg.
None Documented
None Documented
12 hours (terminal); dosing interval adjusted in renal impairment (CrCl <30 mL/min)
5-6 hours in adults with normal renal function; prolonged to 15-20 hours in severe renal impairment (CrCl <10 mL/min).
Renal: 70% unchanged; fecal: 15%; biliary: 10%
Renal: 85-95% as unchanged drug and metabolites; biliary/fecal: <5%.
Category C
Category C
Antiemetic
Antiemetic